Filing Details
- Accession Number:
- 0001209191-16-143056
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-09-28 18:10:56
- Reporting Period:
- 2016-09-26
- Filing Date:
- 2016-09-28
- Accepted Time:
- 2016-09-28 18:10:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1557746 | Aclaris Therapeutics Inc. | ACRS | Pharmaceutical Preparations (2834) | 460571712 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1654337 | Kamil Ali-Jackson | C/O Aclaris Therapeutics, Inc. 101 Lindenwood Drive, Suite 400 Malvern PA 19355 | Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-09-28 | 1,841 | $0.72 | 77,798 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-09-28 | 1,841 | $24.66 | 75,957 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee StockOption (right to buy) | Disposition | 2016-09-26 | 1,841 | $0.00 | 1,841 | $0.72 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,176 | 2024-08-12 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2016.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.31 to $24.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 25% of the shares underlying this option, representing a right to purchase a total of 4,017 shares, vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the issuer as of the applicable vesting date.
Billionaire Hedge Funds
